Hideaki Mizutani

1.2k total citations
25 papers, 579 citations indexed

About

Hideaki Mizutani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hideaki Mizutani has authored 25 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Hideaki Mizutani's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (8 papers). Hideaki Mizutani is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (8 papers). Hideaki Mizutani collaborates with scholars based in Japan, United States and China. Hideaki Mizutani's co-authors include Masahiro Seike, Akihiko Gemma, Yuji Minegishi, Rintaro Noro, Kazuhiro Kitamura, Tetsuya Okano, Akinobu Yoshimura, Kuniko Matsuda, Chie Soeno and Akihiko Miyanaga and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and The Lancet Oncology.

In The Last Decade

Hideaki Mizutani

24 papers receiving 567 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hideaki Mizutani Japan 9 291 225 166 144 123 25 579
Nayara Izabel Viana Brazil 16 420 1.4× 394 1.8× 142 0.9× 175 1.2× 110 0.9× 64 752
Ruoyan Liu China 11 233 0.8× 156 0.7× 147 0.9× 103 0.7× 126 1.0× 26 487
Yinan Guo China 12 240 0.8× 159 0.7× 102 0.6× 114 0.8× 63 0.5× 32 434
Sohachi Nanjo Japan 12 314 1.1× 138 0.6× 74 0.4× 149 1.0× 194 1.6× 38 540
Hidetaka Sugihara Japan 13 313 1.1× 265 1.2× 139 0.8× 124 0.9× 217 1.8× 24 617
Susrutha K. Wickremesekera New Zealand 9 212 0.7× 108 0.5× 228 1.4× 78 0.5× 85 0.7× 17 448
Antonino Belfiore Italy 12 211 0.7× 156 0.7× 157 0.9× 88 0.6× 48 0.4× 20 473
Mingxu Da China 11 223 0.8× 103 0.5× 147 0.9× 77 0.5× 73 0.6× 53 407
Anna Fischer Germany 6 195 0.7× 134 0.6× 140 0.8× 39 0.3× 105 0.9× 14 430
Huiyue Dong China 14 302 1.0× 158 0.7× 60 0.4× 76 0.5× 65 0.5× 20 485

Countries citing papers authored by Hideaki Mizutani

Since Specialization
Citations

This map shows the geographic impact of Hideaki Mizutani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideaki Mizutani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideaki Mizutani more than expected).

Fields of papers citing papers by Hideaki Mizutani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideaki Mizutani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideaki Mizutani. The network helps show where Hideaki Mizutani may publish in the future.

Co-authorship network of co-authors of Hideaki Mizutani

This figure shows the co-authorship network connecting the top 25 collaborators of Hideaki Mizutani. A scholar is included among the top collaborators of Hideaki Mizutani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideaki Mizutani. Hideaki Mizutani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reck, Martin, Tudor–Eliade Ciuleanu, Michael Schenker, et al.. (2024). Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.. Journal of Clinical Oncology. 42(16_suppl). 8560–8560. 6 indexed citations
2.
Tozuka, Takehiro, Rintaro Noro, Hideaki Mizutani, et al.. (2024). Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer. Lung Cancer. 191. 107540–107540. 9 indexed citations
3.
4.
Asao, Tetsuhiko, Takehito Shukuya, Yasushi Goto, et al.. (2023). Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101). Clinical Lung Cancer. 24(7). e247–e253. 4 indexed citations
5.
Nishio, Makoto, Yuichiro Ohe, Satoshi Ikeda, et al.. (2023). First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1. International Journal of Clinical Oncology. 28(10). 1354–1368. 4 indexed citations
6.
7.
Carbone, David P., Tudor–Eliade Ciuleanu, Michael Schenker, et al.. (2023). First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).. Journal of Clinical Oncology. 41(17_suppl). LBA9023–LBA9023. 6 indexed citations
8.
Kato, Yasuhiro, Gou Yamamoto, Yasutaka Watanabe, et al.. (2021). Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations. International Journal of Clinical Oncology. 26(6). 1065–1072. 5 indexed citations
9.
Kato, Yasuhiro, Yasutaka Watanabe, Yuki Yamane, et al.. (2020). Reactivation of TB During Administration of Durvalumab After Chemoradiotherapy for Non-Small-Cell Lung Cancer: A Case Report. Immunotherapy. 12(6). 373–378. 12 indexed citations
10.
Shiraishi, Yoshimasa, Haruko Daga, Satoshi Ikeda, et al.. (2019). A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).. Journal of Clinical Oncology. 37(15_suppl). TPS9125–TPS9125. 3 indexed citations
11.
12.
13.
Yamamoto, Gou, Mari Kikuchi, Shiho Kobayashi, et al.. (2017). Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing. International Journal of Oncology. 50(5). 1579–1589. 13 indexed citations
14.
Miura, Yukiko, Yoshinobu Saito, Susumu Takeuchi, et al.. (2016). Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional study. Japanese Journal of Clinical Oncology. 46(7). 674–680. 5 indexed citations
15.
Kitamura, Kazuhiro, Masahiro Seike, Tetsuya Okano, et al.. (2013). MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells. Molecular Cancer Therapeutics. 13(2). 444–453. 161 indexed citations
16.
Yoshimura, Akinobu, Rintaro Noro, Akihiko Miyanaga, et al.. (2012). Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.. PubMed. 32(10). 4473–8. 5 indexed citations
17.
Cao, Mengru, Masahiro Seike, Chie Soeno, et al.. (2012). MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. International Journal of Oncology. 41(3). 869–875. 153 indexed citations
18.
Mizutani, Hideaki, Tetsuya Okano, Yuji Minegishi, et al.. (2010). HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent manner. Oncology Letters. 1(6). 1011–1016. 27 indexed citations
19.
Noro, Rintaro, Akihiko Miyanaga, Tsuneo Shimokawa, et al.. (2009). The Anticancer Effect of Histone Deacetylase Inhibitors and Combination with the Cytotoxic Agents in Lung Cancer Cells: Biological Analyses for Future Clinical Application. Journal of Nippon Medical School. 76(1). 44–46. 2 indexed citations
20.
Seike, Masahiro, et al.. (2009). Epithelial to Mesenchymal Transition of Lung Cancer Cells. Journal of Nippon Medical School. 76(4). 181–181. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nayara Izabel Viana Breakdown of academic impact, for papers by Ruoyan Liu Breakdown of academic impact, for papers by Yinan Guo Breakdown of academic impact, for papers by Sohachi Nanjo Breakdown of academic impact, for papers by Hidetaka Sugihara Breakdown of academic impact, for papers by Susrutha K. Wickremesekera Breakdown of academic impact, for papers by Antonino Belfiore Breakdown of academic impact, for papers by Mingxu Da Breakdown of academic impact, for papers by Anna Fischer Breakdown of academic impact, for papers by Huiyue Dong
Rankless by CCL
2026